March 15, 2024. Chorda Pharma today announced positive top-line results from a clinical trial for studying the skin burning characteristics of Capsadyn™ (0.25%), an over-the-counter topical analgesic formulated as a proprietary capsaicin-based cream with a concentration of 0.25%. Capsadyn™’s burning properties were statistically equal to the placebo cream (p = 0.32). On the other hand, Zostrix® (0.1%), an over-the-counter topical cream with a capsaicin concentration of 0.1%, had burning properties significantly higher than the placebo (p = 0.001).
Download full release.

November 2, 2023. Chorda Pharma has announced that it is now offering Capsadyn™ for sale as an over the counter (OTC) analgesic topical cream. Unlike other topical analgesics containing capsaicin, Capsadyn™ does not irritate or the burn the skin, which improves tolerability and patient adherence to physician recommendations. Capsadyn™ provides a superior alternative to corticosteroids as well as other OTC medications, including non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, which are not safe for long-term treatment of pain. Capsadyn™ contains no opioids and is non-addictive. Capsadyn™ is the first in Chorda’s pipeline of future drugs under development to address these priorities. 
Download full release.

June 27, 2022. The Virginia Innovation Partnership Corporation (VIPC) has notified Chorda Pharma that it will receive a grant from the Commonwealth Commercialization Fund (CCF) for the Commercialization of a Non-Opioid Topical Analgesic. The $75,000 award will be used to help fund the testing, pilot manufacturing, and marketing of Capsadyn™, which offers relief for patients suffering from chronic pain. Download full release.

June 2, 2021. Chorda Pharma is partnering with Carilion Clinic to develop, test, and market non-opioid medications to treat chronic pain. Download full release.

May 4, 2021. Serial entrepreneur and innovator Victor Iannello, Sc.D., has joined Roanoke-based Chorda Pharma as its CEO. Download full release.